Acute VTE Care Transition Order Set (Adult)

Administration

**DOCUMENT PURPOSE**
This order set may be used for adult patients diagnosed with venous thromboembolism (VTE: deep vein thrombosis, pulmonary embolism) who are ready to be transferred from the hospital or emergency department to outpatient care settings.

Direct oral anticoagulants (DOACs) should be considered in preference to non-DOAC therapy (a parenteral anticoagulant such as unfractionated heparin (UFH) or low molecular weight heparin (LMWH) overlapped with warfarin) if the patient is an appropriate candidate\(^{(1)}\). Patients must have the following to be a DOAC candidate:

- Adequate renal function: creatinine clearance (CrCl) >30 mL/min (> 25 mL/min for Apixaban)
- No significant drug interactions (e.g., carbamazepine, antifungals)
- Confirmed financial coverage for medication
- History of good compliance with medications and/or appointments or highly likely to be adherent

**Non-DOAC Therapy for VTE Patients Clinically Unsuitable for DOACs**
Clinician to consider non-DOAC therapy (therapeutic dose parenteral anticoagulants or lead-in parenteral with warfarin) for the following indications\(^{(1)}\):

**THERAPEUTIC DOSE PARENTERAL ANTICOAGULANTS**

- **Cancer-associated venous thromboembolism (CAT):** LMWH monotherapy may be preferred given extensive experience, but DOACs are reasonable if patient meets above DOAC eligibility criteria, is able to tolerate oral medications and/or is unable/unwilling to use LMWH\(^{(2)}\)
- **Pregnancy/breastfeeding:** UFH or LMWH (and occasionally warfarin in breastfeeding only) are preferred
- **Patients with heparin-induced thrombocytopenia (HIT) or a history of HIT:** Consider fondaparinux
- **Patients with severe renal dysfunction (estimated CrCl <15 ml/min or dialysis):** UFH is preferred over LMWH

**LEAD-IN PARENTERAL WITH WARFARIN**

- **Antiphospholipid Antibody Syndrome (APAS)**
- **Severe renal impairment or hemodialysis**
- **Mechanical valve**
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process.

**Factors Influencing Drug Selection**

*Renal and liver characteristics are necessary to determine appropriateness of anticoagulation therapy.*

**RENAL FUNCTION**

- Calculate estimated CrCl using the Cockcroft-Gault formula based on the following:
  - Age: __________
  - Actual body weight: __________ (kg)
  - Gender: __________
  - Serum Creatinine: __________ (mg/dL)
  - Estimated CrCl: __________ (mL/minute)


**LIVER FUNCTION**

- Liver Disease:  
  - No  
  - Yes: Child Pugh Grade: __________

**CHILD PUGH SCORE**

<table>
<thead>
<tr>
<th>Measure</th>
<th>1 point</th>
<th>2 points</th>
<th>3 points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td>&lt; 2</td>
<td>2 - 3</td>
<td>&gt; 3</td>
</tr>
<tr>
<td>Serum albumin (g/dL)</td>
<td>&gt; 3.5</td>
<td>2.8 - 3.5</td>
<td>&lt; 2.8</td>
</tr>
<tr>
<td>INR</td>
<td>Less than 1.7</td>
<td>1.7 – 2.2</td>
<td>Greater than 2.2</td>
</tr>
<tr>
<td>Ascites</td>
<td>None</td>
<td>Mild (or suppressed with medication)</td>
<td>Moderate to Severe (or refractory)</td>
</tr>
<tr>
<td>Hepatic encephalopathy</td>
<td>None</td>
<td>Grade I-II</td>
<td>Grade III-IV</td>
</tr>
</tbody>
</table>

**Note:** The score employs five clinical measures of liver disease. Each measure is scored 1-3, with 3 indicating the worst condition.

- Total score of 5-6: grade A (well-compensated disease)
- Total score of 7-9: grade B (significant functional compromise)
- Total score 10-15: grade C (decompensated disease)

**VTE HISTORY (PLEASE CHECK ALL THAT APPLY)**

- Provoked VTE (e.g. hormone therapy, surgery within 3 months, leg in a cast, recent immobilization ≥ 3 days)
- Unprovoked VTE
- Recurrent proximal DVT or PE
- VTE present on admission
- Other (specify): __________
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process.

### Acute VTE Care Transition Order Set (Adult)

#### Factors Influencing Drug Selection Continued…

**SHARED DECISION-MAKING DISCUSSION**

**Note:** If drug costs are a barrier to filling prescriptions for medication, refer patient to appropriate resources.

- Select all that have been discussed with patient
  - [ ] Bleeding risk/reversal agents
  - [ ] Dosing regimen options (e.g. once vs. twice daily)
  - [ ] Lifestyle factors of drug (e.g. diet, blood draws, activities, taken with meals)
  - [ ] Out-of-pocket medication cost
  - [ ] Other (specify):

#### DOAC STANDARD DOSE

<table>
<thead>
<tr>
<th>DOAC</th>
<th>Apixaban</th>
<th>Rivaroxaban</th>
<th>Edoxaban</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral lead-in (usually LMWH)</td>
<td>None</td>
<td></td>
<td>≥ 5 days, then <strong>SWITCH</strong> to DOAC</td>
<td></td>
</tr>
<tr>
<td>Standard DOAC dose</td>
<td>10 mg PO BID x 7 days, then 5 mg PO BID</td>
<td>15 mg PO BID x 21 days WITH FOOD, then 20 mg PO daily WITH FOOD</td>
<td>60 mg PO daily</td>
<td>150 mg PO BID</td>
</tr>
</tbody>
</table>

#### CONCOMITANT MEDICATION

**DOAC DRUG INTERACTIONS AND DOSE ADJUSTMENTS**

<table>
<thead>
<tr>
<th>DOAC</th>
<th>Apixaban</th>
<th>Rivaroxaban</th>
<th>Edoxaban</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal impairment</td>
<td>Estimated CrCl &lt;25 ml/min: Avoid use</td>
<td>Estimated CrCl &lt;30 ml/min: Avoid use</td>
<td>Estimated CrCl &lt;30 ml/min: Avoid use</td>
<td>Estimated CrCl ≤30 ml/min: Avoid use</td>
</tr>
<tr>
<td>Hepatic impairment</td>
<td>Child-Pugh A: No adjustment needed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Child-Pugh B: Avoid or use with caution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Child-Pugh C: Avoid use</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Body weight**

<table>
<thead>
<tr>
<th></th>
<th>Overweight</th>
<th>Weight &gt;120 kg or BMI over 40: Avoid use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>No adjustment</td>
<td>≤ 60 kg: 30 mg PO daily No adjustment</td>
</tr>
<tr>
<td>Underweight</td>
<td></td>
<td>Weight &lt;50 kg: Avoid use</td>
</tr>
</tbody>
</table>
### Acute VTE Care Transition Order Set (Adult)

**Factors Influencing Drug Selection Continued…**

**CONCOMITANT MEDICATION (4)**

**DOAC DRUG INTERACTIONS AND DOSE ADJUSTMENTS CONTINUED…**

<table>
<thead>
<tr>
<th></th>
<th>Apixaban</th>
<th>Rivaroxaban</th>
<th>Edoxaban</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>PharamcoDYNAMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug interactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avoid or minimize</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>concomitant use of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>antiplatelets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and/or NSAIDs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>whenever possible</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PharamcoKINETIC</td>
<td>Eliminated/metabolized by:</td>
<td>Eliminated by:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug interactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp and/or strong</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3A4 INDUCERS (e.g.,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>barbiturates,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carbamazepine,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phenytoin, primidone,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rifampin, St. John’s</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wort)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-gp INHIBITORS</td>
<td>N/A</td>
<td>30 mg PO daily</td>
<td>Estimated CrCl</td>
<td></td>
</tr>
<tr>
<td>(e.g. amiodarone,</td>
<td></td>
<td></td>
<td>&lt; 50 ml/min:</td>
<td></td>
</tr>
<tr>
<td>carvedilol,</td>
<td></td>
<td></td>
<td>Avoid use</td>
<td></td>
</tr>
<tr>
<td>diltiazem,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dronarodone,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>azithro/clarithro/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>erythromycin, oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>itra/ketoconazole,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>quinidine,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>verapamil)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual P-gp and strong</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP 3A4 INHIBITORS</td>
<td>Decrease induction and maintenance dose by 50%</td>
<td>Avoid use</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>(e.g. clarithromycin,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>oral itra/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ketoconazole,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cobicistat,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>indinavir, ritonavir,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>saquinivir,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>teleprevir)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual P-gp and</td>
<td>Use with caution</td>
<td>Estimated CrCl</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>moderate CYP 3A4</td>
<td></td>
<td></td>
<td>&lt;80 ml/min:</td>
<td></td>
</tr>
<tr>
<td>INHIBITORS (e.g.</td>
<td></td>
<td></td>
<td>Avoid use</td>
<td></td>
</tr>
<tr>
<td>cyclosporine, diltiazem,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dronaderone,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>erythromycin,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>verapamil)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*drug lists are not exhaustive
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process.

---

**Orders**

**OPTIONS FOR TREATMENT APPROACH**

Choose one anticoagulation approach and complete orders as per below:

**DOAC Therapy**

1. **Single Direct Oral Anticoagulant (DOAC) (Rivaroxaban OR Apixaban)**
2. **Lead-in Parenteral with DOAC (Parenteral PLUS Edoxaban OR Dabigatran)**

**Non-DOAC Therapy**

3. **Lead-in Parenteral with Warfarin (Parenteral PLUS Warfarin)**
4. **Therapeutic Dose Parenteral Only (Dalteparin OR Enoxaparin OR Fondaparinux OR Other)**

---

**DOAC THERAPY**

1. **SINGLE DIRECT ORAL ANTICOAGULANT (DOAC) (RIVAROXABAN OR APIXABAN)**

Choose one DOAC and de-escalate dose on ____________________________ (date)

**APIXABAN**

- Apixaban two 5 mg tablets (10 mg total), PO twice daily for first 7 days, followed by one 5 mg tablet (5 mg total), PO twice daily
- Apixaban starter pack (single fill for first month of therapy), followed by one tablet (5 mg total), PO twice daily
- Other (specify): __________________________________________________________________________

**RIVAROXABAN (CHOOSE ONLY ONE)**

- Rivaroxaban 15 mg PO twice daily with food for 21 days, followed by 20 mg PO once daily with food
- Rivaroxaban starter pack (single fill for first month of therapy) PO daily with food, followed by 20 mg PO once daily with food
- Other (specify): __________________________________________________________________________

---
**Orders Continued**

**DOAC THERAPY CONTINUED**

2. **Lead-in Parenteral with DOAC (Parenteral plus Edoxaban or Dabigatran)**

Choose (a) for requisite 5 day parenteral lead-in, then (b) to switch to DOAC on _______ (date).

a. **Parenteral Lead-In (choose only one)**

   **Dalteparin**
   - □ 200 IU/kg every 24 hours administered subcutaneously for at least 5 days

   **Enoxaparin (choose only one)**
   - □ 1 mg/kg every 12 hours administered subcutaneously at the same time every day for at least 5 days
   - □ 1.5 mg/kg once a day administered subcutaneously at the same time every day for at least 5 days
   - □ Other (specify):

   **Fondaparinux (choose only one)**
   - □ Fondaparinux 5 mg (body weight <50 kg) subcutaneously once daily. Treatment should continue for at least 5 days
   - □ Fondaparinux 7.5 mg (50 to 100 kg), subcutaneously once daily. Treatment should continue for at least 5 days
   - □ Fondaparinux 10 mg (>100 kg) subcutaneously once daily. Treatment should continue for at least 5 days
   - □ Other (specify):

   **Other Parenteral Anticoagulant**
   - □ Other (specify):

b. **DOAC Requiring Parenteral Lead-In (choose only one)**

   **Dabigatran**
   - □ Dabigatran 150 mg PO twice daily (must leave in original package, take with full glass of water), preceded by parenteral lead-in indicated below
   - □ Other (specify):

   **Edoxaban (choose only one)**
   - □ Edoxaban 60 mg PO once daily, preceded by parenteral lead-in indicated below (CrCl greater than ≥ 51 mL/minute)
   - □ Edoxaban 30 mg PO once daily, preceded by parenteral lead-in indicated below (CrCl 30 to 50 mL/minute, with body weight less than or equal to 60 kg, or concomitant P-gp Inhibitor)
   - □ Other (specify):
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process.

### Non-DOAC Therapy

#### 3. Lead-in Parenteral with Warfarin (Parenteral Plus Warfarin)

Choose (a) for requisite 5 day parenteral lead-in and until INR >2, then (b) to switch to Warfarin on (date).

##### a. Parenteral Lead-In (choose only one)

- **Dalteparin**
  - [ ] 200 IU/kg every 24 hours administered subcutaneously for at least 5 days

- **Enoxaparin (choose only one)**
  - [ ] 1 mg/kg every 12 hours administered subcutaneously at the same time every day for at least 5 days
  - [ ] 1.5 mg/kg once a day administered subcutaneously at the same time every day for at least 5 days
  - [ ] Other (specify):

- **Fondaparinux (choose only one)**
  - [ ] Fondaparinux 5 mg (body weight <50 kg) subcutaneously once daily. Treatment should continue for at least 5 days
  - [ ] Fondaparinux 7.5 mg (50 to 100 kg), subcutaneously once daily. Treatment should continue for at least 5 days
  - [ ] Fondaparinux 10 mg (>100 kg) subcutaneously once daily. Treatment should continue for at least 5 days
  - [ ] Other (specify):

##### b. Warfarin Requiring Parenteral Lead-In (choose only one)

- [ ] Warfarin 5 mg PO once daily, then request Physician, NP/PA, Pharmacist, or Anticoagulation Clinic to reassess and adjust
  - Consider lower starting doses of warfarin for elderly patients (e.g. >75 yr) and/or those with low body weight (less than or equal to 50 kg)

- [ ] Warfarin 2.5 mg PO once daily, then request Physician, NP/PA, Pharmacist, or Anticoagulation Clinic to reassess and adjust

- [ ] Warfarin ______________ PO once daily, then request Physician, NP/PA, Pharmacist, or Anticoagulation Clinic to reassess and adjust

- [ ] Other (specify):

---

© 2018 ACForum. All rights reserved. Unauthorized use, reproduction or disclosure is prohibited.
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

### Orders Continued

#### NON-DOAC THERAPY CONTINUED

4. **THERAPEUTIC DOSE PARENTERAL ONLY (Dalteparin OR Enoxaparin OR Fondaparinux OR OTHER)**

**Dalteparin (choose only one)**
- [ ] 200 IU/kg every 24 hours administered subcutaneously for 30 days, then 150 IU/kg every 24 hours administered subcutaneously
- [ ] 200 IU/kg every 24 hours administered subcutaneously for at least 5 days

**Enoxaparin (choose only one)**
- [ ] 1 mg/kg every 12 hours administered subcutaneously at the same time every day for at least 5 days
- [ ] 1.5 mg/kg once a day administered subcutaneously at the same time every day for at least 5 days
- [X] Other (specify): ______________________________________________________

**Fondaparinux (choose only one)**
- [ ] Fondaparinux 5 mg (body weight <50 kg) subcutaneously once daily. Treatment should continue for at least 5 days
- [ ] Fondaparinux 7.5 mg (50 to 100 kg), subcutaneously once daily. Treatment should continue for at least 5 days
- [ ] Fondaparinux 10 mg (>100 kg) subcutaneously once daily. Treatment should continue for at least 5 days
- [X] Other (specify): ______________________________________________________

**Other Parenteral Anticoagulant**
- [ ] Other (specify): ______________________________________________________
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

### Acute VTE Care Transition Order Set (Adult)

#### Orders Continued

**BASELINE LAB ORDERS**
- [ ] Baseline CBC (for ALL)
- [ ] Baseline serum creatinine (for ALL)
- [ ] Other (specify): ____________________________

**FOLLOW-UP LAB ORDERS**

**DOACS**
- [ ] Monitor renal function q3-12 months (e.g. serum creatinine, CrCl)
- [ ] Anticoagulant clinic referral as per policy/procedure \(^1,^5\)
- [ ] Other (specify): ____________________________

**NON-DOAC/WARFARIN THERAPY**

**INR**
- [ ] Target INR 2 – 3
- [ ] INR q3-4 days for 2 weeks, then as instructed by clinician or anticoagulation clinic
- [ ] Anticoagulant clinic referral as per policy/procedure \(^1,^5\)
- [ ] Other (specify): ____________________________

#### Other Considerations

**ANTIPLATELET THERAPY**

**Note:** Patients who take multiple anti-thrombotic agents (aspirin, NSAIDs, P2Y12 inhibitors [e.g. clopidogrel, prasugrel, ticagrelor] and anticoagulants) are at increased risk for bleeding complications. Clinicians should review the risk-benefit ratio for each medication and consider minimizing bleeding risk whenever possible \(^6\).

- [ ] Patient should **continue** current ASA therapy
- [ ] Patient should **DIScontinue** current ASA therapy
- [ ] Patient should **continue** current P2Y-12 therapy
- [ ] Patient should **DIScontinue** current P2Y-12 therapy
- [ ] Other (specify): ____________________________

---

Submitted by:  
Practitioner:  
© 2018 ACForum. All rights reserved. Unauthorized use, reproduction or disclosure is prohibited.
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

### Acute VTE Care Transition Order Set (Adult)

#### Other Considerations Continued

**PROTON PUMP INHIBITORS (PPIS)**

**Note:** Clinician may consider PPI for patients at high risk of GI bleeding, particularly if using multiple antithrombotic agents or with a prior history of upper GI bleeding (7, 8, 9). PPIs may decrease serum concentrations of the active metabolite(s) of dabigatran. PPIs are optimally taken 30 minutes before breakfast.

- [ ] dexlansoprazole 30 mg PO once daily
- [ ] esomeprazole 20 mg PO once daily (avoid concomitant use with clopidogrel)
- [ ] lansoprazole __________ mg PO once daily (15 – 30 mg)
- [ ] omeprazole 20 mg PO once daily (avoid concomitant use with clopidogrel)
- [ ] pantoprazole ______________ mg PO once daily (20 – 40 mg)
- [ ] rabeprazole 20 mg PO once daily
- [ ] Other (specify): __________________________________________

#### Patient Education

Provide applicable education and discharge instruction to the patient as per policy/procedure(1, 10).

The following topics are important to include within patient education:

- [ ] Follow-up appointments for blood work
- [ ] Follow-up contact information: ________________________________
- [ ] Safety net phone number to call if any barriers or issues after discharge: ____________________
- [ ] Medication management, including starting/stopping new medication, missed doses and dose change (dose de-escalation or switch to oral therapy at appropriate date/time)
- [ ] Importance of medication adherence
- [ ] Expected duration of anticoagulation therapy
- [ ] Appropriate medication storage
- [ ] Drug/diet considerations
- [ ] Bleeding and bruising risks
- [ ] When to seek medical attention (e.g. warning signs for bleeding, symptoms of recurrent VTE)
- [ ] Written education materials for patient/family/caregivers to review after discharge
- [ ] Importance of social support
- [ ] Medication reconciliation completed

#### Referrals

- [ ] Anticoagulation Clinic: ____________________________
- [ ] Primary Care Provider: _______________________
- [ ] Hematology: ____________________________
- [ ] Oncology: ____________________________
- [ ] Vascular Specialist: ____________________________
- [ ] Other: ____________________________
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

<table>
<thead>
<tr>
<th>Additional Orders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Reference Document Only

© 2018 ACForum. All rights reserved. Unauthorized use, reproduction or disclosure is prohibited.
Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process.

Acute VTE Care Transition Order Set (Adult)

References

All medications have been reviewed using Lexicomp Online.


